INNOVODIGM PRIVATE LIMITED

In their own words

Innovodigm (India’s first reported vaccine micro-array patch company) is developing a proprietary vaccine microarray patch (MAP) platform that combines precise microneedle engineering with a thermostability-oriented formulation/coating approach—enabling needle-free delivery, simplified logistics, reduced medical waste, and potential dose-sparing.By reducing reliance on cold-chain and simplifying administration, the platform directly supports India’s universal immunization priorities under the National Health Mission by addressing last-mile reachability and workforce constraints.Quantified impact (India + global):India reachability gap: WHO-UNICEF (WUENIC) reporting cited by UNICEF indicates ~2.7 million “zero-dose” children in India in 2021, improving to ~1.1 million in 2022—showing both the scale of the challenge and the impact of improved delivery systems.Child lives saved baseline: Immunization already averts an estimated ~4.4 million deaths globally each year; technologies that expand coverage and reduce drop-outs can meaningfully add to this impact over time.Cross-contamination / unsafe injection reduction: Eliminating needles and syringes directly reduces sharps exposure and associated infections; classic global burden estimates attribute ~66,000 HBV, ~16,000 HCV, and ~1,000 HIV infections (per year, among healthcare workers from occupational sharps injuries in year-2000 estimates) to percutaneous exposures—MAPs remove this route for vaccinators and reduce reuse risks in low-resource settings.Disease burden context: World Health Organization reports ~1.1 million deaths from hepatitis B in 2022, while WHO’s HIV data reports ~630,000 HIV-related deaths worldwide in 2024—underscoring why safer, broader vaccine reach (especially for Hep B) matters at population scaleCurrent status, partnerships, funding, grants & prizesCurrent status (commercialization readiness): Seed-funded, scaling process/infrastructure and moving through third-party preclinical validation with clinical trials expected to begin in 2026Backed by support including DST, DBT-BIRAC, and ICMR Lab-to-Market, Innovodigm has secured over ₹5.5 crore in seed funding led by IAN and PadUp Ventures to scale operations, expand infrastructure, and initiate clinical validation. Its innovative work has earned national recognition, being awarded as one of the Top 2 Technologies by the Government of India among 200 startups at the Nanoelectronics Mission Roadshow, and Top 2 in Eastern India. Innovodigm has represented India at prestigious forums including the G20 Summit and the Digital India Conclave, underscoring its mission to democratize vaccine access through scalable, Make-in-India health technologies.

Written by the company on its public Startup India profile. Not verified by us.